Beacon Roofing Supply Inc.
Total Consideration
$10.79B
Share price: $124.35
Purchase-Price Allocation
Goodwill
$5.11B
Deferred Tax Liability
$910.3M
Pro-Forma Combined Entity
Revenue
$9.54B
Net Income
−$332.4M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 7.00% | 61.00% | -3.00% | 5.00% | 10.70% | 2.60% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | -3.00% | 0.00% | — | — | — | -0.60% |
| Valuation Allowance Change | 0.00% | 6.00% | 1.00% | 5.00% | -0.20% | 0.00% |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | 21.00% | 4.07% | 41.00% | 22.00% | 45.00% | 17.10% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $47.4K | $178.0K | −$192.2K | −$297.0K | $22.8M | −$57.7M |
| Income Taxes Paid (Cash) | — | — | — | $301.0K | — | $38.2M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$10.79B
Share price: $124.35
Purchase-Price Allocation
Goodwill
$5.11B
Deferred Tax Liability
$910.3M
Pro-Forma Combined Entity
Revenue
$9.54B
Net Income
−$332.4M
Total Consideration
$2.25B
Share price: $40.00
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance And Employee Related Costs | Employee Severance | +$55M | $28M | $26M |
| Stock Based Compensation Expense | Other | +$41M | — | — |
| Lease Abandonment Costs | Facility Closing | +$5M | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).